GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Compugen Ltd (NAS:CGEN) » Definitions » YoY Rev. per Sh. Growth

CGEN (Compugen) YoY Rev. per Sh. Growth : 0.00% (As of Jun. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Compugen YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Compugen's YoY Rev. per Sh. Growth for the quarter that ended in Jun. 2024 was 0.00%.

Compugen's Revenue per Share for the three months ended in Jun. 2024 was $0.08.

Compugen YoY Rev. per Sh. Growth Historical Data

The historical data trend for Compugen's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Compugen YoY Rev. per Sh. Growth Chart

Compugen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -100.00 - 184.00 22.54 339.08

Compugen Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 334.48 - -

Compugen YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Compugen's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2023 )
=(Revenue per Share (A: Dec. 2023 )-Revenue per Share (A: Dec. 2022 ))/ | Revenue per Share (A: Dec. 2022 ) |
=(0.382-0.087)/ | 0.087 |
=339.08 %

Compugen's YoY Rev. per Sh. Growth for the quarter that ended in Jun. 2024 is calculated as:

YoY Rev. per Sh. Growth (Q: Jun. 2024 )
=(Revenue per Share (Q: Jun. 2024 )-Revenue per Share (Q: Jun. 2023 )) / | Revenue per Share (Q: Jun. 2023 )) |
=(0.075-0)/ | 0 |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Compugen YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Compugen's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Compugen Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Compugen Ltd (NAS:CGEN) » Definitions » YoY Rev. per Sh. Growth
Comparable Companies
XTAE:BLRX XTAE:BONS XTAE:GFC-M XTAE:DNA XTAE:CANF XTAE:CBI XTAE:MTLF XTAE:EVGN XTAE:XTLB XTAE:KDST VRTX REGN ASX:CSL XKRX:207940 XBRU:UCB ALNY XBRU:ARGX XKRX:068270 BNTX BGNE
Traded in Other Exchanges
CGEN:Israel
Address
26 Harokmim Street, Building D, Azrieli Center, Holon, ISR, 5885849
Website
https://www.cgen.com
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.